-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Versigent, Lowers Price Target to $58

Benzinga·10/06/2026 09:35:51
Listen to the news
Goldman Sachs analyst Mark Delaney maintains Versigent (NYSE:VGNT) with a Buy and lowers the price target from $59 to $58.